PURPOSE: To assess short-term real-world visual and anatomic outcomes in patients with neovascular age-related macular degeneration (nvAMD) following a protocol shift from an individualized treat-and-extend (T&E) anti-VEGF regimen to a fixed-interval injection schedule without routine imaging during the early COVID-19 pandemic. This evidence concerns the gene VEGFA and COVID-19.